We report the results of administering CD20 monoclonal antibody ( 
Treatment of ALL with conventional chemotherapy results in complete remission (CR) in 60-70% of patients. However, a high proportion of patients achieving a CR will relapse. [1] [2] [3] When cytogenetic or molecular analyses (PCR) reveal the presence of bcr-abl gene rearrangement in ALL, the risk of relapse is very high. This finding constitutes a poor prognostic factor. 4 In these patients, allogeneic bone marrow transplantation is the only effective therapy, applicable to 30-40% of patients. [5] [6] [7] Autologous BMT during early first CR is associated with 20-30% disease-free survival at 3 years, a high incidence of relapse being the main cause of treatment failure. 2, 8 One important reason for the development of relapse after autologous BMT may be the infusion of leukemic cells with the graft. To avoid this, most centers perform marrow purging in vitro. 2, 3 Although its efficacy has not been firmly demonstrated, recent reports suggest that marrow purging may prolong disease-free survival in patients with AML receiving autografts in first CR. 3, 9 In contrast to AML, purging in ALL is usually performed with MoAb specific for antigens on leukemic cells. This method provides a median depletion of three logs of target cells but usually fails to achieve BCR-ABL negativity in the inoculum. 2, 10 An alternative to in vitro purging may be to administer monoclonal antibodies in vivo prior to stem cell harvest. Recently, the chimeric anti-CD20 MoAb, Rituximab (MabThera), approved as a single agent for the treatment of relapse/refractory low grade or follicular nonHodgkin's lymphoma, has occasionally been used for in vivo purging of stem cells in patients with lymphoma. 9 We describe the successful use of Rituximab (Genentech Inc, San Francisco, CA, USA) before stem cell mobilization to remove CD20 + cells from the harvest and to reduce leukemic cells from the marrow, in a patient with bcr-abl ALL who underwent autologous BMT.
Case report
A 32-year-old man was diagnosed with bcr-abl-positive ALL (FAB L1) in September 1999. The leukemic immunophenotype at diagnosis was CD20, CD19, CD10, CD20, HLA DR, TdT and CD34 positive and CD2, CD5, CD13, CD41, and CD61 negative. Cytogenetic study showed a karyotype of 46 XY. The patient was treated with one course of chemotherapy with vincristine, daunorubicin, lasparaginase (L-ASA) and cyclophosphamide (PETHEMA protocol) followed by a second cycle with vincristine, methotrexate, cytosine arabinoside (Ara-C), L-ASA and 6-mercaptopurine. Due to resistance to front-line treatment the patient received rescue chemotherapy consisting of vindesine, mitoxantrone, cyclophosphamide and high doses of Ara-C and methotrexate. A morphological CR was obtained, although persistence of 2% leukemic cells was evident by flow cytometry. 11 For this reason a second course of rescue therapy was administered. After this treatment, a bone marrow aspirate confirmed the morphological CR and the persistence of 1.75% cells with leukemic phenotype. In addition, PCR analysis demonstrated the bcrabl gene rearrangement in this marrow sample.
The patient lacked an HLA-matched donor, and for this reason autologous bone marrow transplant with purged marrow was proposed. Since the leukemic cells had moderate expression of CD20 antigen in their surface, anti-CD20 MoAb Rituximab was considered a valid option for in vivo treatment (Figure 1a taneously, therapy with IM methotrexate (40 mg/week) and 6-mercaptopurine (100 mg/day) was given. This treatment was tolerated well and no complications were observed. After treatment was completed, the percentage of blast cells by flow cytometry had decreased to Ͻ0.1% and bcr-abl rearrangement was not detectable (Figure 1e, f, g ). Two weeks later, the patient developed bilateral Pneumocystis carinii pneumonia. After solving this complication, while remaining in CR, cyclophosphamide 1.5 g/m 2 and G-CSF 16 g/kg, were administered as mobilization therapy. Stem cells were collected using a large volume apheresis procedure which resulted in obtaining 2.7 × 10 6 CD34/kg. Of note, PBSC collected were not contaminated with bcr-ablpositive cells. The patient is now under preparative regimen for autologous PBSC transplantation.
Discussion
A bcr-abl-positive ALL patient in morphological remission underwent investigational in vivo purging of minimal residual disease in the marrow. Because of a strong positivity for CD20 antigen in the blast cells, we hypothesized that CD20 MoAb could eliminate residual leukemia. This was the case and abnormal CD20
+ cells decreased to 0.1% with disappearance of bcr-abl rearrangement in PCR analyses of bone marrow cells. Furthermore, a tumor-free PBSC harvest was obtained after this modality of in vivo purging. This is of particular interest, since ex vivo treatment usually fails to obtain a bcr-abl-negative product. In addition, Rituximab in vivo therapy may avoid the toxicity of additional chemotherapy courses given with the intention of eliminating minimal residual disease before PBSC harvest. Furthermore, Rituximab may be a useful tool to treat or prevent leukemia relapses after autografts. A close monitoring of CD20
+ cells with aberrant immunophenotype, in marrow samples after transplant, may be recommended for the administration of this MoAb at early relapse. In summary, the results presented encourage us to further investigate this approach in bcr-abl-positive ALL patients who are candidates for autologous transplantation. Larger series with extended follow-up will contribute to defining the role of Rituximab in the therapeutic armamentarium for these patients.
